You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes

    SBC: VALA SCIENCES, INC.            Topic: NHLBI

    Cardiotoxicity is a leading cause of drug discovery attrition across all of preclinical and clinical drug discovery. While the FDA and the Comprehensive in vitro Proarrhythmia Assay initiative (CiPA) are focused primarily on predicting proarrhythmic effects, drug attrition due to cardiomyopathy, or primary cardiac cytotoxicity, may be even more prevalent, is typically currently only carried out vi ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a portable beat-to-beat fetal ECG system

    SBC: AUSCULTECH DX LLC            Topic: NICHD

    Project Summary There are 24,000 stillbirths per year in the United States, and 2.6 million stillbirths per year worldwide, with no significant decrease in the last decade. Abnormal fetal heart rhythms, such as long QT syndrome, are thought to play an important role in these deaths, and may cause 3- 10% of unexplained stillbirths. This is in addition to known fetal arrhythmias, which affect 1-3% o ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Glove-based Tactile Streaming of Braille Characters and Digital Images for the Visually Impaired

    SBC: HAPTX INC            Topic: NEI

    This project will achieve a computerized system that supplies digital content, both lexical and graphical, suitable for children, students and working adults of the Visually Impaired (VId) community, to increase their autonomy and potentiate their Quality of Life and societal contribution. While there is notable academic research, such as a high-density pin display tablet, there is no commercial, ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. An Efficacy Trial of Mobile Technology for Reducing and Preventing Adolescent Suicide

    SBC: OUI THERAPEUTICS INC            Topic: 104

    ABSTRACT Suicide is a leading cause of death in the US and suicide rates have steadily increased. Despite this, there is a paucity of interventions that reduce suicide ideation and behavior. In this project, we seek to enhance a beta version of our suicide prevention digital therapeutic (developed in phase I) and conduct a randomized controlled trial to evaluate the efficacy of the digital therape ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. A decellularized porcine placenta matrix hydrogel for management of radiation-induced proctitis

    SBC: Briopryme Biologics, Inc.            Topic: 102

    PROJECT SUMMARY Radiation therapy is a widely used treatment modality for pelvic malignancies such as prostate and cervical cancer; however, the high doses needed to confer therapeutic benefit often inflict significant damage on the normal issue in and surrounding the radiation field. The most frequent complication of pelvic radiation is proctitis, which nearly all patients experience acutely and ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Testing the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsy

    SBC: NEURAEGIS INC            Topic: 103

    AbstractEpilepsy is the most prevalent neurological diseases after migraines. Current antiepileptic drug treatments mainly attempt to reduce excitation or enhance inhibition in order to control seizures. Unfortunately, such therapeutics result in a number of undesirable side-effects, and demonstrate limited efficacy against drug- resistant cases of epilepsy. So far, no treatment has been developed ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Clusterin Targeting of Ocular Surface Disease

    SBC: PROTERIS BIOTECH, INC.            Topic: NEI

    PROJECT SUMMARYThe ocular surface (OcS) comprises the stratified squamous epithelia of the cornea/conjunctiva, its adnexa, and the overlying tear film. OcS disease disrupts the normal developmental progression, maturation, and turnover of OcS epithelia, causing “epitheliopathy” characterized by cell damage, barrier disruption and programmed cell death. OcS disease initiated by tear dysfunction ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Audiom: Developing an Indoor Non-Visual Mapping System

    SBC: XR NAVIGATION INC            Topic: NEI

    Project Abstract Indoor navigation for blind and visually impaired individuals (BVIs) within unfamiliar locations is typically an incredibly anxiety-provoking and stressful experience for numerous reasons, e.g., inaccessible signage including directories and venue maps, and if braille signs do exist, they are difficult to find, lack directional information, and are useless to the BVIs who do not r ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a virtual reality guided acupuncture imagery treatment for Chronic low back pain

    SBC: MASSACHUSETTS NEURO TECHNOLOGY, INC.            Topic: NCCIH

    Project Summary Low back pain (LBP) is one of the most common reasons for physician visits in the USA. A substantial number of chronic LBP (cLBP) patients do not adequately respond to current treatment options. Thus, the development of new treatments for cLBP is urgently needed. The use of imagery to treat illness, including chronic pain, is one of the oldest medical practices. Although still unde ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic Agents Targeting Cryptococcal Infections

    SBC: Quercus Molecular Design, LLC            Topic: NIAID

    Cryptococcus species are a clinically important group of opportunistic fungal pathogens that can cause life threatening disease, particularly in the immunocompromised patient population. Historically, this has involved patients with advanced HIV, but is becoming more prevalent in other immunovulnerable populations. The primary pathogens, C. neoformans and C. gattii, are ubiquitous in the environme ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government